Navigation Links
2 microRNAs promote spread of tumor cells
Date:1/28/2008

(Philadelphia) The more scientists learn about microRNAs short strands of RNA that can interfere with normal gene activity the more obvious it becomes how closely they are associated with cancer. In a new study, scientists at The Wistar Institute and their colleagues have identified two microRNAs (miRNAs) that promote tumors deadly spread, or metastasis. One of the miRNAs may provide an early warning of metastatic breast cancer and the need for aggressive treatment.

By blocking the translation of tumor suppressor genes, miRNAs have been shown to facilitate the development of many types of cancer. In a study that will be published February 1 in Nature Cell Biology and is available online, the researchers describe how two miRNAs transformed non-invasive human breast cancer cells into cells that rapidly metastasized in cell cultures and laboratory mice.

Of the 450 miRNAs we tested, we found two, miR-373 and miR-520c, that induced cell migration in MCF-7 cells a line of human breast cancer cells that normally does not metastasize, says Qihong Huang, M.D., Ph.D., an assistant professor in Wistars Molecular and Cellular Oncogenesis Program and lead author and co-corresponding author on the study.

In 2006, miR-373 was identified as a possible oncogene a modified gene that causes cancer in testicular cancer. According to Huang, miR-520c is a new miRNA whose function has not been known until now.

Our most surprising finding is that miR-373 and isoforms of miR-520 are part of the same family, Huang says. Their seed sequences, or first eight nucleotides, are all very similar. It suggests this family of miRNAs could target similar genes and have important biological and pathological functions in cancer development and metastasis.

Another intriguing characteristic of these two miRNAs is that they are not found in normal adult cells only in tumor cells. They are not in normal testis, but are expressed in testicular cancer, Huang says. We see them in breast cancer cells, especially metastatic cells, but not in normal breast cells.

After they confirmed the metastasis-inducing properties of the miRNAs, the research team began searching for their target genes in MCF-7 cells. Several experiments limited the search to a gene called CD44, which contains genetic instructions for a common cell surface receptor molecule. Found in most cell types, CD44 affects cell-cell interactions and interactions between cells and their microenvironments. It also has been shown to inhibit tumor metastasis.

When CD44 was downregulated, non-metastatic MCF-7 cells became metastatic. When the scientists injected MCF-7 cells without CD44 into immunodeficient mice, the mice developed bone and lung tumors, while mice receiving MCF-7 cells with CD44 did not.

We found that miR-373 and miR-520c interfered with the expression of CD44 in MCF-7 cells, Huang says. We think there are additional targets involved, but our results suggest that these miRNAs promote cell metastasis at least in part by limiting the expression of CD44.

In the final stages of the study, Huang and his colleagues analyzed 11 pairs of primary and metastatic breast cancer tissue samples from cancer patients. The scientists found that metastatic tumors removed from lymph nodes contained more miR-373 than the primary breast tumor from the same patient.

An additional study of 72 human primary breast tumors found higher mean expression of miR-373, and lower mean expression of CD44, in primary tumors from patients whose cancer had spread to their lymph nodes compared to patients whose tumors had not spread.

According to Huang, these results suggest miR-373 has the potential to become an important early biomarker for metastatic breast cancer. As far as we know, miR-373 is not expressed in normal tissue, Huang says. So if we detect miR-373 in lymph nodes when a patients breast tumor is removed, it would indicate that cancer cells have spread and the patient will need more aggressive therapy.

Huang plans additional studies to explore the use of miR-373 in the diagnosis of metastatic breast cancer. Also, because he has found the inhibition of miR-373 to reduce tumor migration and invasion, he plans to investigate its potential to treat breast cancer and other cancers.


'/>"/>

Contact: Abbey J. Porter
aporter@wistar.org
215-898-3943
The Wistar Institute
Source:Eurekalert

Related medicine news :

1. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
2. Gentiva(R) Health Services Promotes Boelsen to Senior Vice President, CareCentrix(R)
3. China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Womens Health Issues
4. Hormonal dietary supplements might promote prostate cancer progression
5. The First Annual LOVE L.A. Show Promotes Sensuality, Relationships and Sexual Education
6. Photo: MultiVu Promotes George DeTorres to Divisional Vice President for the MultiVu Healthcare Team
7. A healthy smile may promote a healthy heart
8. Isolagen Inc. Promotes Declan Daly to Chief Executive Officer (CEO)
9. Some Immature Brain Cells May Promote Tumors
10. Therap Services Promotes Allison Dudo to Assistant Director of Training
11. FOXO factor promotes survival of oxygen-deprived cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
Breaking Medicine Technology: